Jeffrey Peters Net Worth

Jeffrey Peters biography

Jeffrey J. Peters serves as Director of the Company. He has over 25 years of medical device experience and currently serves as the president and chief executive officer of Cardialen, a private medical device company developing low-energy therapy for cardiac arrhythmias. Previously, Mr. Peters was the chief executive officer of Anulex Technologies (2011-2014), a company developing minimally invasive spine therapies. He also served as the chief technology officer of ev3 (now Medtronic) from 2001-2007. Mr. Peters' financial roles include portfolio manager at Black River Asset Management, entrepreneur-in-residence at Foundation Medical, and stock analyst at Dain Rauscher Wessels. Mr. Peters received his B.S. and M.B.A. from the University of Minnesota. Mr. Peters brings experience in the medical device and life science industries to the Board.

What's Jeffrey Peters's mailing address?

Jeffrey's mailing address filed with the SEC is Cruiser Lane, Belgrade, Gallatin County, Montana, 59714, United States.

Insiders trading at Xtant Medical Inc

Over the last 9 years, insiders at Xtant Medical Inc have traded over $104,833 worth of Xtant Medical Inc stock and bought 5,164,288 units worth $21,623,047 . The most active insiders traders include Stavros G. Vizirgianakis, Advisors Llc Orbimed und Matthew Rizzo. On average, Xtant Medical Inc executives and independent directors trade stock every 117 days with the average trade being worth of $134,096. The most recent stock trade was executed by Kevin D Brandt on 17 November 2023, trading 41,670 units of XTNT stock currently worth $50,004.

What does Xtant Medical Inc do?

xtant medical (nyse mkt: xtnt) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. with core competencies in both biologic and non-biologic surgical technologies, xtant can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. for further information, please visit xtantmedical.com.

Xtant Medical Inc executives and stock owners

Xtant Medical Inc executives and other stock owners filed with the SEC include:

• Sean E. Browne,
  Pres, CEO & Director
• Kevin D. Brandt,
  Sr. VP & Chief Commercial Officer
• Darrel Holmes,
  Chief Operating Officer
• Gregory Juda,
  Chief Scientific Officer
• Rich Cockrell,
  IR Contact Officer
• Matthew Rizzo,
  Director
• Jeffrey Peters,
  Director
• Robert McNamara,
  Director
• Michael Eggenberg,
  Director
• John Bakewell,
  Director
• Kevin Brandt,
  Senior Vice President, Chief Commercial Officer
• Greg Jensen,
  Chief Financial Officer, Vice President - Finance
• Sean Browne,
  President, Chief Executive Officer, Director
• Kevin M. O'Dare,
  VP of Sales - Eastern US
• Catherine Lundy,
  VP of HR
• Scott Neils,
  Interim CFO & Controller
• Scott C Neils,
  Chief Financial Officer
• Jonn R. Beeson,
  Director
• Eric Bernard Timko,
  Director
• Kent L Swanson,
  Director
• John Arthur Deedrick,
  Director
• David Louis Kirschman,
  EVP & Chief Scientific Officer
• Daniel S Goldberger,
  Chief Executive Officer
• Rudy A Mazzocchi,
  Director
• Jon M. Wickwire,
  
• David Goodman,
  
• Paul Buckman,
  Director
• Michael A Lopach,
  Director
• Advisors Llc Orbimed,
  Director
• Kathie J. Lenzen,
  Chief Financial Officer
• Carl O'connell,
  Chief Executive Officer
• Michael Mainelli,
  Interim CEO
• Ronald G. Berlin,
  VP & Chief Operations Officer
• Advisors Llc Orbimed Rof Ii...,
  
• Lori D Mitchell Keller,
  Director
• Mark A. Schallenberger,
  Chief Operations Officer
• Stavros G. Vizirgianakis,
  Director